

ITRON INC /WA/  
Form 4  
October 02, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Ziegler Lynda L.

(Last) (First) (Middle)  
2111 NORTH MOLTER ROAD  
(Street)  
LIBERTY LAKE, WA 99019  
(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ITRON INC /WA/ [ITRI]

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/01/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	10/01/2015		A	787 A \$ 0	8,248	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: ITRON INC /WA/ - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ziegler Lynda L. 2111 NORTH MOLTER ROAD LIBERTY LAKE, WA 99019		X		

## Signatures

MariLyn R. Hill, attorney-in-fact for Ms. Ziegler  
 10/02/2015  
 Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. 1,926 Changes in operating assets and liabilities: Accounts

receivable.....	13,479	15,940	Inventories and other	
assets.....	(9,481)	11,517	Accounts payable.....	7,833
12,376 Income taxes.....		2,331	3,818 Due to third party	
payors.....	(12,687)	54,648	Other accrued liabilities.....	
105,383 55,914 -----			Net cash provided by operating activities before reorganization costs....	154,734
166,501 Payment of reorganization costs.....	(5,806)	(12,267)	-----	Net cash
provided by operating activities.....	148,928	154,234	-----	Cash flows from investing
activities: Purchase of property and equipment.....	(42,445)	(72,629)	Sale of	
assets.....	15,161	9,400	Surety bond	
deposits.....	(4,647)	(16,763)	Net change in	
investments.....	(34,932)	6,377	Collection of notes	
receivable.....	1,469	-	Other.....	100 (3,688)
-----			Net cash used in investing activities.....	(65,294) (77,303) -----
flows from financing activities: Net change in lines of credit.....			-	55,000
long-term debt.....	(14,336)	(22,446)	Payment of debtor-in-possession deferred	

financing costs.....	(800)	(3,688)	Payment of deferred financing costs.....	-
(2,068) Other.....			(12,901) (36,935) -----	Net cash used in
financing activities.....	(28,037)	(10,137)	-----	Change in cash and cash
equivalents.....	55,597	66,794	Cash and cash equivalents at beginning of	
period.....	148,350	34,551	-----	Cash and cash equivalents at end of
period.....	\$203,947	\$ 101,345	=====	Supplemental information: Interest
payments.....			\$ 8,539	\$ 34,193
refunds.....	606	3,668	See accompanying notes. 5	KINDRED HEALTHCARE,

INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE 1 -- BASIS OF PRESENTATION Kindred Healthcare, Inc. ("Kindred" or the "Company") (formerly Vencor, Inc.) provides long-term healthcare services primarily through the operation of nursing centers and hospitals. At September 30, 2000, the Company's health services division operated 317 nursing centers (40,535 licensed beds) in 31 states and a rehabilitation therapy business. The Company's hospital division operated 56 hospitals (4,886 licensed beds) in 23 states and an institutional pharmacy business. The Company and substantially all of its subsidiaries filed voluntary petitions for protection under Chapter 11 of Title 11 of the United States Code (the "Bankruptcy Code") on September 13, 1999. The Company currently is operating its businesses as a debtor-in-possession subject to the jurisdiction of the United States Bankruptcy Court in Delaware (the "Bankruptcy Court"). Accordingly, the unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the American Institute of Certified Public Accountants Statement of Position 90-7, "Financial Reporting by Entities in Reorganization Under the Bankruptcy Code" ("SOP 90-7") and generally accepted accounting principles applicable to a going concern, which assumes that assets will be realized and liabilities will be discharged in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the resolution of the Chapter 11 Cases (as defined) or other matters discussed in the accompanying notes. The Company's continued operating losses, liquidity issues and the Chapter 11 Cases raise substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern and the appropriateness of using the going concern basis of accounting are dependent upon, among other things, (i) the Company's ability to comply with the terms of the DIP Financing (as defined), (ii) confirmation of a plan of reorganization under the Bankruptcy Code, (iii) the Company's ability to achieve profitable operations after such confirmation, and (iv) the Company's ability to generate sufficient cash from operations to meet its obligations. The proposed plan of reorganization submitted by the Company and other actions during the Chapter 11 Cases could change materially the amounts currently recorded in the unaudited condensed consolidated financial statements. See Note 4. On May 1, 1998, Ventas, Inc. ("Ventas") completed the spin-off (the "Spin-off") of its healthcare operations to its stockholders through the distribution of Vencor common stock. Ventas retained ownership of substantially all of its real property and leases such real property to the Company pursuant to four master lease agreements. In anticipation of the Spin-off, the Company was incorporated on March 27, 1998 as a Delaware corporation. For accounting purposes, the consolidated historical financial statements of Ventas became the historical financial statements of the Company upon consummation of the Spin-off. Any discussion concerning events prior to May 1, 1998 refers to the Company's business as it was conducted by Ventas prior to the Spin-off. The Company regularly reviews the carrying value of certain long-lived assets in accordance with Statement of Financial Accounting Standards No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of" ("SFAS 121"). SFAS 121 requires impairment losses to be recognized for long-lived assets used in operations when indications of impairment are present and the estimate of undiscounted future cash flows is not sufficient to recover asset carrying amounts. Operating results for the third quarter and nine months ended September 30, 2000 include asset impairment charges of \$1.0 million and \$6.6 million, respectively. The accompanying unaudited condensed consolidated financial statements do not include all of the disclosures normally required by generally accepted accounting principles or those normally required in annual reports on Form 10-K. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 1999 filed with the Securities and Exchange Commission on Form 10-K. 6 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 1 -- BASIS OF PRESENTATION (Continued) The accompanying unaudited condensed consolidated financial statements have been prepared in

accordance with the Company's customary accounting practices and the provisions of SOP 90-7. Management believes that the financial information included herein reflects all adjustments necessary for a fair presentation of interim results and, except for the transactions described in Notes 3, 6 and 7, all such adjustments are of a normal and recurring nature. In the fourth quarter of 1999, the Company realigned its Vencare ancillary services business. Vencare's rehabilitation, speech and occupational therapy businesses were integrated into the Company's health services division, and its institutional pharmacy business was assigned to the hospital division. Vencare's respiratory therapy and certain other ancillary businesses were discontinued. The accompanying unaudited condensed consolidated financial statements reflect the realignment of the former Vencare business for all periods presented.

Effective January 1, 2000, the Company adopted an amortization period of 20 years from the date of acquisition for goodwill. Prior thereto, the Company generally amortized such costs over 40 years. Certain prior period amounts have been reclassified to conform with the current period presentation. NOTE 2 -- RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS On August 14, 2001, the Company announced that it will restate certain of its previously issued consolidated financial statements. The Company recently determined that an oversight related to the allowance for professional liability risks had occurred in its consolidated financial statements beginning in 1998. The oversight resulted in the understatement of the provision for professional liability claims in 1998, 1999 and 2000 because the Company did not record a reserve for claims incurred but not reported at the respective balance sheet dates. The cumulative understatement of professional liability claims reserves approximated \$5 million at December 31, 1998, \$28 million at December 31, 1999 and \$39 million at December 31, 2000. The restatement had no effect on previously reported cash flows from operations. The unaudited condensed consolidated financial statements included herein amend those previously included in the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2000. Consolidated financial statement information and related disclosures included in these amended unaudited condensed consolidated financial statements reflect, where appropriate, changes resulting from the restatement.

7 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 2 -- RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Continued) The effect of the restatement on the Company's previously issued unaudited condensed consolidated financial statements follows (in thousands, except per share amounts): Three months ended September 30, Nine months ended September 30, ----- 2000 1999 2000 1999

	As previously reported	As previously reported	As previously reported	As previously reported	As previously reported
Loss from operations...	\$(26,564)	\$(29,357)	\$(42,442)	\$(47,996)	\$(47,527)
Net loss.....	(26,564)	(29,357)	(42,442)	(47,996)	(47,527)
Loss per common share: Basic:					
Loss from operations.....	\$ (0.38)	\$ (0.42)	\$ (0.61)	\$ (0.69)	\$ (0.69)
Net loss.....	(0.38)	(0.42)	(0.61)	(0.69)	(0.69)
Diluted Loss from operations.....	\$ (0.38)	\$ (0.42)	\$ (0.61)	\$ (0.69)	\$ (0.69)
Net loss.....	(0.38)	(0.42)	(0.61)	(0.69)	(0.69)
Professional liability risks.....	\$ 58,657	\$ 94,749	\$ 45,072	\$ 72,785	\$ 72,785
Total liabilities.....	1,687,956	1,724,048	1,612,540	1,640,253	1,640,253
Accumulated deficit.....	(1,111,268)	(1,147,360)	(1,062,957)	(1,090,670)	(1,090,670)
Stockholders' deficit.....	(426,554)	(462,646)	(378,309)	(406,022)	(406,022)

NOTE 3 -- ACCOUNTING CHANGE Effective January 1, 1999, the Company adopted the provisions of the American Institute of Certified Public Accountants Statement of Position 98-5, "Reporting on the Costs of Start-Up Activities" ("SOP 98-5"), which requires the Company to expense start-up costs, including organizational costs, as incurred. In accordance with the provisions of SOP 98-5, the Company wrote off \$8.9 million of such unamortized costs as a cumulative effect of change in accounting principle in the first quarter of 1999. NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE On September 13, 1999, the Company and substantially all of its subsidiaries filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code. The Chapter 11 cases have been consolidated for purposes of joint administration under Case Nos. 99-3199 (MFW) through 99-3327 (MFW) (collectively, the "Chapter 11 Cases"). The Company currently is operating its businesses as a debtor-in-possession subject to the jurisdiction of the Bankruptcy Court. Proposed Plan of Reorganization On September 29, 2000, the Company filed its plan of

reorganization (the "Proposed Plan") with the Bankruptcy Court. The Proposed Plan represents a step toward finalizing a consensual arrangement among the Company's senior bank lenders (the "Senior Lenders"), holders of the Company's \$300 million 9 7/8% Guaranteed Senior Subordinated Notes due 2005 (the "1998 Notes"), the Department of Health and Human Services' Office of the Inspector General acting on behalf of the United States government (the "Government") and the advisors to the official committee of unsecured creditors. The Bankruptcy Court previously had extended the Company's exclusive right to submit a plan of reorganization through September 29, 2000. 8

KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Proposed Plan of Reorganization (Continued) The Company is continuing its negotiations with Ventas regarding the treatment to be provided to Ventas in the Proposed Plan. The Company believes, however, that it has substantially completed the negotiation of the broad economic terms of the amended master lease agreements with Ventas. The Proposed Plan incorporates these terms and compromise positions to the remaining unresolved issues between the Company and Ventas. The Company also is continuing to work with the Government to finalize the precise terms of its settlement. The economic terms of the Company's settlement with the Government have been agreed upon as well as the precise language of a Corporate Integrity Agreement (as defined) that will take effect upon the Company's emergence from bankruptcy. In addition to the factors noted herein, confirmation and consummation of the Proposed Plan are subject to a number of material conditions including, without limitation, the receipt of the requisite acceptances from various creditor classes to confirm the Proposed Plan and the Bankruptcy Court's determination that the Proposed Plan satisfies the statutory requirements for confirmation under the Bankruptcy Code. There can be no assurance that the Proposed Plan as submitted will be confirmed or consummated. The following is a summary of certain material provisions of the Proposed Plan. The summary does not purport to be complete and is qualified in its entirety by reference to all of the provisions of the Proposed Plan, including all exhibits and documents described therein, as filed with the Bankruptcy Court and as may otherwise be amended and/or supplemented. The Proposed Plan would provide for, among other things, the following distributions: Senior Lender Claims - The Senior Lenders would receive, in the aggregate, new senior subordinated secured notes in the principal amount of \$300 million, bearing interest at the rate of LIBOR plus 4 1/2%, with a maturity of seven years (the "New Senior Subordinated Secured Notes"). The interest on the New Senior Subordinated Secured Notes would begin to accrue after the first two fiscal quarters following the effective date of the Proposed Plan and, in lieu of interest payments, the Company would pay a \$25.9 million obligation under the Government Settlement (as defined) in the first two fiscal quarters following the effective date of the Proposed Plan, as described below. In addition, holders of the Senior Lender claims would receive an aggregate distribution of 65.5% of the new common stock (the "New Common Stock") of the reorganized Company (subject to dilution from stock issuances occurring after the effective date of the Proposed Plan). Senior Subordinated Noteholder Claims - The holders of the 1998 Notes and the remaining \$2.4 million of the Company's 8 5/8% Senior Subordinated Notes due 2007 (collectively, the "Subordinated Noteholder Claims") would receive, in the aggregate, 24.5% of the New Common Stock (subject to dilution from stock issuances occurring after the effective date of the Proposed Plan). In addition, the holders of the Subordinated Noteholder Claims would receive, in the aggregate, warrants issued by the Company for the purchase of an aggregate of 7,000,000 shares of New Common Stock, with a five-year term, which would consist of warrants to purchase 2,000,000 shares at a price per share equal to an assumed \$450 million aggregate equity value of the Company, and warrants to purchase 5,000,000 shares at a price per share equal to an assumed \$500 million aggregate equity value. 9

KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Proposed Plan of Reorganization (Continued) Ventas Claim - Ventas would receive the following treatment under the Proposed Plan: Four new master leases with Ventas will be assumed as amended, and will replace the original Master Lease Agreements (as defined) as of the effective date of the Proposed Plan (the "Amended Leases"). The principal economic terms of the Amended Leases are as follows: (a) A decrease of \$52 million in the aggregate minimum rent from the annual rent as of May 1, 1999 to a new initial aggregate minimum rent of \$174.6 million as of the effective date of the Proposed Plan. (b) A 2% annual cash escalator in the aggregate minimum rent (beginning on May 1, 2001), and a 1.5% annual accrued rent escalator (with an interest accrual at 6% per annum), which would become payable in cash and converted to a cash escalator on a prospective basis upon the repayment or refinancing of the New Senior

Subordinated Secured Notes. (c) A one-time option, that can be exercised by Ventas 5 1/2 years after the effective date of the Proposed Plan, to reset the aggregate minimum rent under the Amended Leases to the then current fair market rental in exchange for a payment of \$5 million to the Company. (d) Under the Amended Leases, the "Event of Default" provisions also would be substantially modified. In addition to the Amended Leases, Ventas would receive a distribution of 10% of the New Common Stock (subject to dilution from stock issuances occurring after the effective date of the Proposed Plan). Ventas also would enter into a tax escrow agreement with the Company that provides for the escrow of a \$26 million Federal income tax refund received in 2000 and certain other Federal and state income taxes until the expiration of the applicable statutes of limitation for the auditing of the refunds. The escrowed funds would be available for payment of certain tax deficiencies, if any, during the escrow period. At the end of the escrow period, the Company would be entitled to 100% of the proceeds in the escrow account. All other agreements between the Company and Ventas, except those modified by the Proposed Plan, would be assumed by the Company as of the effective date of the Proposed Plan. United States Claim - Subject to obtaining applicable government approvals, the claims of the Government (other than claims of the Internal Revenue Service and non-monetary criminal claims, if any) would be settled under an agreement entered into with the Company and Ventas which would be incorporated into the Proposed Plan (the "Government Settlement"). Under the Government Settlement, the Company would pay the Government a total of \$25.9 million, which would be paid as follows: (i) \$10 million on the effective date of the Proposed Plan and (ii) an aggregate of \$15.9 million during the first two fiscal quarters following the effective date, plus accrued interest at the rate of 6% per annum beginning as of the effective date of the Proposed Plan. Ventas would pay the Government a total of \$103.6 million, which would be paid as follows: (i) \$34 million on the effective date of the Proposed Plan and (ii) the remainder paid over five years, bearing interest at the rate of 6% per annum beginning as of the effective date of the Proposed Plan. In addition, the Company would repay the remaining balance of the 10 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Proposed Plan of Reorganization (Continued) obligations under the HCFA Agreement (as defined) (approximately \$67.5 million as of September 30, 2000) pursuant to the terms previously agreed to by the Company. See "- Events Leading to Reorganization." As previously announced, the Company has entered into a Corporate Integrity Agreement (the "Corporate Integrity Agreement") with the Department of Health and Human Services' Office of the Inspector General ("OIG") as part of the overall Government Settlement. Under the Corporate Integrity Agreement, the Company will implement a comprehensive internal quality improvement program in its nursing centers and long-term hospitals and its regional and corporate offices. As part of the Corporate Integrity Agreement, the Company will retain staff at the University of Wisconsin's Center for Health Services Research and Analysis ("CHSRA"), to assist in developing an internal quality improvement program. CHSRA also will monitor and evaluate the Company's program and report its findings to the OIG. The Corporate Integrity Agreement must be approved by the Bankruptcy Court and would become effective concurrent with the Company's emergence from Chapter 11. General Unsecured Creditors Claims - The general unsecured creditors of the Company would be paid the full amount of their allowed claims existing as of the date of the Company's filing for protection under the Bankruptcy Code. These amounts would be paid in equal quarterly installments over three years with interest at the rate of 6% per annum from the effective date of the Proposed Plan, subject to certain exceptions. A convenience class of unsecured creditors, consisting of creditors holding allowed claims in an amount less than or equal to an amount to be established by the Company, would be paid in full on the effective date of the Proposed Plan. Preferred Stockholder and Common Stockholder Claims - The holders of preferred stock and common stock of the Company would not receive any distributions under the Proposed Plan. The preferred stock and common stock would be cancelled on the effective date of the Proposed Plan. Other Significant Provisions - The board of directors of the reorganized Company would consist of: (i) Edward L. Kuntz; (ii) four directors selected by the holders of the claims of the Senior Lenders; and (iii) two directors selected by the holders of the Subordinated Noteholder Claims. A performance share plan would be approved under the Proposed Plan that provides for the distribution of 600,000 shares of New Common Stock to certain key employees of the Company. The shares would be distributed to participants in three installments based upon the Company's achievement of certain aggregate equity values. In addition, a new stock option plan would be approved under the Proposed Plan for the issuance of stock options for up to 600,000 shares of New Common Stock to certain key employees of the Company. The Proposed Plan also would provide for the continuation of the Company's current

retention plan for its key employees and the payment of certain performance bonuses upon the effective date of the Proposed Plan. Ventas has announced that it does not support the Proposed Plan and that it will require changes on substantive issues before Ventas will support the Proposed Plan. 11 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Proposed Plan of Reorganization (Continued) First Amendment to Proposed Plan - On or about November 6, 2000, the Company filed its first amended plan of reorganization (the "Amended Plan") with the Bankruptcy Court. The Company also filed a first amended disclosure statement and a short-form disclosure statement (the "Disclosure Materials"), which, if approved by the Bankruptcy Court, will be used to solicit acceptances of the Amended Plan. The Company intends to seek approval of the Disclosure Materials at a hearing before the Bankruptcy Court on December 6, 2000. The Amended Plan amends the Proposed Plan by including the terms of the Government Settlement, which Government Settlement remains subject to appropriate governmental approval and resolution of certain issues including the scope of releases being provided in conjunction with the Government Settlement.

Debtor-in-Possession Financing Agreement In connection with the Chapter 11 Cases, the Company entered into a \$100 million debtor-in-possession financing agreement (the "DIP Financing"). The Bankruptcy Court granted final approval of the DIP Financing on October 1, 1999. The DIP Financing was initially comprised of a \$75 million tranche A revolving loan (the "Tranche A Loan") and a \$25 million tranche B revolving loan (the "Tranche B Loan"). Interest is payable at the prime rate plus 2 1/2% on the Tranche A Loan and the prime rate plus 4 1/2% on the Tranche B Loan. Available aggregate borrowings under the Tranche A Loan were initially limited to \$45 million in September 1999 and increased to \$65 million in October, \$70 million in November and \$75 million thereafter. Pursuant to the most recent amendment to the DIP Financing, the aggregate borrowing limitations under the Tranche A Loan are limited to approximately \$48 million until maturity and are reduced for asset sales made by the Company. Borrowings under the Tranche B Loan require the approval of lenders holding at least 75% of the credit exposure under the DIP Financing. The DIP Financing is secured by substantially all of the assets of the Company and its subsidiaries, including certain owned real property. The DIP Financing contains standard representations and warranties and other affirmative and restrictive covenants. At September 30, 2000, there were no outstanding borrowings under the DIP Financing. Since the consummation of the DIP Financing, the Company and the lenders under the DIP Financing (the "DIP Lenders") have agreed to several amendments to the DIP Financing. These amendments approved various changes to the DIP Financing including (i) extending the period of time for the Company to file its plan of reorganization, (ii) approving certain transactions, (iii) revising the Company's cash plan originally submitted with the DIP Financing and (iv) revising certain financial covenants. In the most recent amendment to the DIP Financing, the parties agreed, among other things, to extend the maturity date of the DIP Financing until January 31, 2001 and to revise and update certain financial covenants. In addition, the most recent amendment extends the period of time for the Company to file a plan of reorganization and disclosure statement and an appropriate motion requesting confirmation and consummation thereof to November 22, 2000. At December 31, 1999, the Company was not in compliance with the DIP Financing covenant related to the minimum Net Amount of Eligible Accounts (accounts receivable). Since there were no outstanding borrowings under the DIP Financing at December 31, 1999, the event of default had no effect on the Company's 1999 consolidated financial statements. Effective April 12, 2000, the Company and the DIP Lenders agreed to an 12 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Debtor-in-Possession Financing Agreement (Continued) amendment to the DIP Financing to revise the covenant related to the minimum Net Amount of Eligible Accounts. In that amendment, the DIP Lenders also waived all events of default regarding this covenant that occurred prior to the date of the amendment. On June 12, 2000, the Company entered into a commitment letter (the "Commitment Letter") with certain of the DIP Lenders to finance an amended and restated debtor-in-possession credit agreement in an aggregate principal amount of \$90 million (the "Restated DIP"). The Restated DIP would become effective in the event the Company became involved in a legal proceeding against Ventas. The Commitment Letter was initially scheduled to expire on August 31, 2000 unless the Company obtained Bankruptcy Court approval of the Commitment Letter and paid all fees payable upon such approval. On August 31, 2000, the Company and the certain DIP Lenders agreed to an amendment to extend the date by which Bankruptcy Court approval must be obtained through October 31, 2000. On October 23, 2000, the Company and the

certain DIP Lenders agreed to a further amendment to extend the date for Bankruptcy Court approval to January 31, 2001. The Bankruptcy Court approved this latest amendment to the Commitment Letter on October 25, 2000. The consummation of the Restated DIP also would be subject to other customary conditions contained in the Commitment Letter. At this time, the Company has adjourned the hearing seeking approval of the Commitment Letter and the Restated DIP in light of the status of the current negotiations with its major constituencies to finalize the terms of the Proposed Plan.

**Events Leading to Reorganization** The Company reported a net loss from operations in 1998 aggregating \$578 million, resulting in certain financial covenant violations under the Company's \$1.0 billion bank credit facility (the "Credit Agreement"). Namely, the covenants regarding minimum net worth, total leverage ratio, senior leverage ratio and fixed charge coverage ratio were not satisfied at December 31, 1998. Prior to the commencement of the Chapter 11 Cases, the Company received a series of temporary waivers of these covenant violations. The waivers generally included certain borrowing limitations under the \$300 million revolving credit portion of the Credit Agreement. The final waiver was scheduled to expire on September 24, 1999. The Company was informed on April 9, 1999 by the Health Care Financing Administration ("HCFA") that the Medicare program had made a demand for repayment of approximately \$90 million of reimbursement overpayments by April 23, 1999. On April 21, 1999, the Company reached an agreement with HCFA to extend the repayment of such amounts over 60 monthly installments (the "HCFA Agreement"). Under the HCFA Agreement, non-interest bearing monthly payments of approximately \$1.5 million commenced in May 1999. Beginning in December 1999, interest accrues on the balance of the overpayments at a statutory rate approximating 13.4%, resulting in a monthly payment of approximately \$2.0 million through March 2004. If the Company is delinquent with two consecutive payments, the HCFA Agreement will be defaulted and all subsequent Medicare reimbursement payments to the Company may be withheld. Amounts due under the HCFA Agreement aggregated \$67.5 million at September 30, 2000 and have been classified as liabilities subject to compromise in the Company's unaudited condensed consolidated balance sheet. The Company has received Bankruptcy Court approval to continue to make the monthly payments under the HCFA Agreement during the pendency of the Chapter 11 Cases. On May 3, 1999, the Company elected not to make the interest payment of approximately \$14.8 million due on the 1998 Notes. The failure to pay interest resulted in an event of default under the 1998 Notes.

**13 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued)** Events Leading to Reorganization (Continued) In accordance with SOP 90-7, outstanding borrowings under the Credit Agreement (\$509.1 million) and the principal amount of the 1998 Notes (\$300 million) are presented as liabilities subject to compromise in the Company's unaudited condensed consolidated balance sheet at September 30, 2000. If the Chapter 11 Cases had not been filed, the Company would have reported a working capital deficit approximating \$900 million at September 30, 2000. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the resolution of the Chapter 11 Cases or other matters discussed herein. During the pendency of the Chapter 11 Cases, the Company is continuing to record the contractual amount of interest expense related to the Credit Agreement. No interest costs have been recorded related to the 1998 Notes since the filing of the Chapter 11 Cases. Contractual interest expense not accrued for the 1998 Notes during the third quarter and the nine months ended September 30, 2000 were \$7.4 million and \$22.2 million, respectively. As previously reported, the Company was informed by the Department of Justice (the "DOJ") that the Company and Ventas are the subjects of ongoing investigations into various Medicare reimbursement issues, including hospital cost reporting issues, Vencare billing practices and various quality of care issues in the hospitals and nursing centers formerly operated by Ventas and currently operated by the Company. The Company has cooperated fully in these investigations. The DOJ has informed the Company that it has intervened in several pending qui tam actions asserted against the Company and/or Ventas in connection with these investigations. In addition, the DOJ has filed proofs of claims with respect to certain alleged claims in the Chapter 11 Cases. See Note 11. The Company believes that the DOJ's intervention in these actions will facilitate the ability of the parties to reach a final resolution. The Company and Ventas are continuing settlement discussions with the DOJ to finalize the Government Settlement to resolve all of the DOJ investigations including the pending qui tam actions.

**Agreements with Ventas** On March 18, 1999, the Company served Ventas with a demand for mediation pursuant to the Agreement and Plan of Reorganization governing the Spin-off (the "Spin-off Agreement"). The Company was seeking a reduction in rent and other concessions under its lease agreements with Ventas (the "Master Lease Agreements"). On March 31, 1999, the Company and Ventas entered into a standstill agreement (the



"Standstill Agreement") which provided that both companies would postpone through April 12, 1999 any claims either may have against the other. On April 12, 1999, the Company and Ventas entered into a second standstill agreement (the "Second Standstill") which provided that neither party would pursue any claims against the other or any other third party related to the Spin-off as long as the Company complied with certain rent payment terms. The Second Standstill was scheduled to terminate on May 5, 1999. The Company and Ventas also agreed that any statutes of limitations or other time-related constraints in a bankruptcy or other proceeding that might be asserted by one party against the other would be extended and tolled from April 12, 1999 until May 5, 1999 or until the termination of the Second Standstill (the "Tolling Agreement"). As a result of the Company's failure to pay rent, Ventas served the Company with notices of nonpayment under the Master Lease Agreements. Subsequently, the Company and Ventas entered into further amendments to the Second Standstill and the Tolling Agreement to extend the time during which no remedies may be pursued by either party and to extend the date by which the Company may cure its failure to pay rent.

14 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 --

PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Agreements with Ventas (Continued) In connection with the Chapter 11 Cases, the Company and Ventas entered into a stipulation (the "Stipulation") which provides for the payment by the Company of a reduced monthly rent of approximately \$15.1 million beginning in September 1999. The Stipulation was approved by the Bankruptcy Court. The difference between the \$19.3 million base rent under the Master Lease Agreements and the reduced monthly rent is being accrued as an administrative expense subject to compromise in the Chapter 11 Cases. Unpaid August 1999 rent of approximately \$18.9 million, constituting a claim by Ventas in the Chapter 11 Cases, is potentially subject to dispute. The Stipulation also continues to toll any statutes of limitations or other time constraints in a bankruptcy proceeding for claims that might be asserted by the Company against Ventas. The Stipulation automatically renews for one-month periods unless either party provides a 14-day notice of termination. The Stipulation also may be terminated prior to its expiration upon a payment default by the Company, the consummation of a plan of reorganization or the occurrence of certain defaults under the DIP Financing. The Stipulation also provides that the Company will continue to fulfill its indemnification obligations arising from the Spin-off. If the Company and Ventas are unable to resolve their disputes or maintain an interim resolution, the Company may seek to pursue claims against Ventas arising out of the Spin-off and seek judicial relief barring Ventas from exercising any remedies based on the Company's failure to pay some or all of the rent to Ventas. The Company's failure to pay rent or otherwise comply with the Stipulation, in the absence of judicial relief, would result in an "Event of Default" under the Master Lease Agreements. Upon an Event of Default under the Master Lease Agreements, assuming Ventas were to be granted relief from the automatic stay by the Bankruptcy Court, the remedies available to Ventas include, without limitation, terminating the Master Lease Agreements, repossessing and reletting the leased properties and requiring the Company to (i) remain liable for all obligations under the Master Lease Agreements, including the difference between the rent under the Master Lease Agreements and the rent payable as a result of reletting the leased properties or (ii) pay the net present value of the rent due for the balance of the terms of the Master Lease Agreements. Such remedies, however, would be subject to the supervision of the Bankruptcy Court. On May 31, 2000, the Company announced that the Bankruptcy Court had approved a tax stipulation agreement between the Company and Ventas (the "Tax Stipulation"). In connection with the Spin-off, the Company and Ventas entered into a tax allocation agreement under which Ventas agreed that the Company would be entitled to any tax refunds associated with its former healthcare operations. In February 2000, a Federal tax refund in excess of \$26 million was received by Ventas. The Company has asserted that it is entitled to the refund under several grounds, including the terms of the existing tax allocation agreement. Accordingly, the Company demanded that Ventas enter into the Tax Stipulation which provides that certain refunds of Federal, state and local taxes received by either party on or after September 13, 1999 be held by the recipient of such refunds in segregated interest bearing accounts. The Tax Stipulation requires notification before either party can withdraw funds from the segregated accounts.

15 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 --

PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) General On September 14, 1999, the Company received approval from the Bankruptcy Court to pay pre-petition and post-petition employee wages, salaries, benefits and other employee obligations. The Bankruptcy Court also approved orders granting authority, among other things, to pay pre-petition claims of certain critical vendors, utilities and patient obligations.

All other pre-petition liabilities are classified in the unaudited condensed consolidated balance sheet as liabilities subject to compromise. The Company currently is paying the post-petition claims of all vendors and providers in the ordinary course of business. On November 4, 1999, the Company received approval (subject to certain conditions) to implement a management retention plan (the "Management Retention Plan") to enhance the ability of the Company to retain key management employees during the reorganization period. Under the Management Retention Plan, bonuses aggregating \$7.3 million will be awarded to certain key management employees based upon various percentages of their annual salary. The Management Retention Plan provides that the retention bonuses be paid in three equal amounts upon: (i) the Bankruptcy Court's approval of the Management Retention Plan, (ii) the effective date of a plan of reorganization and (iii) three months following the effective date of a plan of reorganization. Under the Bankruptcy Code, actions to collect pre-petition indebtedness against the Company are subject to an automatic stay and other contractual obligations against the Company may not be enforced. The automatic stay does not necessarily apply to certain actions against Ventas for which the Company has agreed to indemnify Ventas in connection with the Spin-off. In addition, the Company may assume or reject executory contracts, including lease obligations, under the Bankruptcy Code. Parties affected by these rejections may file claims with the Bankruptcy Court in accordance with the reorganization process. A substantial portion of pre-petition liabilities are subject to settlement under the Proposed Plan submitted by the Company. The Proposed Plan must be voted upon by certain of the impaired creditors of the Company and approved by the Bankruptcy Court. There can be no assurance that the Proposed Plan submitted by the Company will be approved by the requisite holders of claims, confirmed by the Bankruptcy Court or that it will be consummated. If the Proposed Plan is not accepted by the required number of impaired creditors and the Company's exclusive right to file and solicit acceptance of the Proposed Plan ends, any party in interest may subsequently file its own plan of reorganization for the Company. A plan of reorganization must be confirmed by the Bankruptcy Court after certain findings required by the Bankruptcy Code are made by the Bankruptcy Court. The Bankruptcy Court may confirm a plan of reorganization notwithstanding the non-acceptance of the plan by an impaired class of creditors or equity holders if certain requirements of the Bankruptcy Code are satisfied.

16 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 4 -- PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE (Continued) Liabilities Subject to Compromise "Liabilities subject to compromise" refers to liabilities incurred prior to the commencement of the Chapter 11 Cases. These liabilities, consisting primarily of long-term debt, amounts due to third party payors and certain accounts payable and accrued liabilities, represent the Company's estimate of known or potential claims to be resolved in connection with the Chapter 11 Cases. Such claims remain subject to future adjustments based on assertions of additional claims, negotiations, actions of the Bankruptcy Court, further developments with respect to disputed claims, future rejection of executory contracts or unexpired leases, determination as to the value of any collateral securing claims, treatment under a confirmed plan of reorganization and other events. Proposed payment terms for these amounts are set forth in the Proposed Plan. All pre-petition liabilities, other than those for which the Company has received Bankruptcy Court approval to pay, are classified in the unaudited condensed consolidated balance sheet as liabilities subject to compromise. A summary of the principal categories of claims classified as liabilities subject to compromise under the Chapter 11 Cases follows (in thousands):

September 30, 2000	December 31, 1999	-----	-----	-----	-----
Agreement.....	\$ 509,143	\$ 506,114	1998 Notes.....	300,000	300,000
HCFA Agreement...	67,469	80,296	8 5/8% Senior Subordinated Notes.....	2,391	2,391
financing costs... (10,883)	(12,626)	Other.....	3,185	4,592	-----
-----	-----	-----	-----	-----	871,305
-----	-----	Due to third party payors.....	117,477	112,694	Accounts payable.....
Accrued liabilities: Interest.....	78,959	45,521	Ventas rent.....	69,519	33,884
Other.....	52,140	52,858	-----	200,618	132,263
-----	-----	-----	-----	-----	\$1,220,577

\$1,159,417 ===== Substantially all of the liabilities subject to compromise would have been classified as current liabilities if the Chapter 11 Cases had not been filed.

17 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 5 -- REVENUES Revenues are recorded based upon estimated amounts due from patients and third party payors for the provision of healthcare services, including anticipated settlements under reimbursement agreements with Medicare, Medicaid and other third party payors. A summary of revenues by payor type follows (in thousands):

Edgar Filing: ITRON INC /WA/ - Form 4

2000	1999	2000	1999	----- Medicare.....	\$253,054	\$225,483	\$ 765,988	\$ 719,451
Medicaid.....	238,783	237,403	681,858	680,785	Private and other... 239,095	233,205	740,926	716,694
				----- 730,932	696,091	2,188,772	2,116,930	Elimination..... (13,679)
				----- \$717,253	\$681,924	\$2,146,133	\$2,071,048	=====

NOTE 6 -- UNUSUAL TRANSACTIONS Operating results for each period presented include certain unusual transactions. These transactions are included in other operating expenses in the unaudited condensed consolidated statement of operations for the respective periods in which they were recorded. In the third quarter of 2000, the Company recorded a \$9.2 million write-off of an impaired investment. Operating results for the nine months ended September 30, 2000 also included a \$4.5 million gain on the sale of a closed hospital. Operating results for the nine months ended September 30, 1999 included a \$15.2 million write-off of the Company's remaining investment in a healthcare related entity and a \$5.6 million charge for the cancellation of a nursing center software development project. NOTE 7 -- REORGANIZATION COSTS Reorganization costs, consisting principally of professional fees, aggregated \$4.7 million and \$5.4 million in the third quarters of 2000 and 1999, respectively, and \$10.3 million and \$12.3 million for the respective nine month periods. NOTE 8 -- EARNINGS PER SHARE Basic and diluted earnings per common share are based upon the weighted average number of common shares outstanding. No incremental shares were included in the calculations of the diluted loss per common share since the results would be antidilutive.

18 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 9 -- BUSINESS SEGMENT DATA The Company operates two business segments: the health services division and the hospital division. The health services division operates nursing centers and a rehabilitation therapy business. The hospital division operates hospitals and an institutional pharmacy business. The Company defines operating income as earnings before interest, income taxes, depreciation, amortization and rent. Operating income reported for each of the Company's business segments excludes allocations of corporate overhead. The following table sets forth the Company's revenues, operating results and assets by business segment (in thousands): Quarter Nine Months

				----- 2000	1999	2000	1999	----- Revenues: Health services division:
Nursing centers.....				\$420,588	\$399,907	\$1,246,450	\$1,196,211	Rehabilitation services.....
	34,032	46,088	101,582	150,687	Other ancillary services.....			(1)
10,477	(8)	39,595	Elimination.....	(19,671)	(31,770)	(56,271)	(100,539)	-----
				----- 434,948	424,702	1,291,753	1,285,954	Hospital division: Hospitals.....
244,391	230,682	748,009	704,072	Pharmacy.....	51,593	40,707	149,010	126,904
				----- 295,984	271,389	897,019	830,976	----- 730,932
				----- 696,091	2,188,772	2,116,930	Elimination of pharmacy charges to Company nursing centers...	(13,679)
				----- (45,882)	----- \$717,253	\$681,924	\$2,146,133	\$2,071,048
				----- =====	=====	=====	=====	=====
				----- Income (loss) from operations (restated):	Operating income (loss):	Health services division:	Nursing centers.....	\$ 69,493
	2,837	5,191	2,264	20,349	Other ancillary services.....	2,687	1,333	
3,059	5,964		75,017	58,246	218,876	188,025	Hospital division:	
			47,284	52,871	154,229	168,512	Pharmacy.....	
1,075	585	664	7,825	48,359	53,456	154,893	176,337	Corporate overhead.....
				----- (29,993)	(27,299)	(87,113)	(84,750)	Unusual transactions.....
				----- (9,236)	- (4,701)	(20,827)	Reorganization costs.....	(4,745)
				----- (5,443)	(10,340)	(12,302)	-----	
				-----	Operating income.....	79,402	78,960	271,615
				-----	246,483			Rent.....
	(77,870)	(77,423)	(230,878)	(228,963)	Depreciation and amortization.....	(17,464)	(24,126)	(53,534)
	(12,925)	(25,357)	(41,609)	(63,652)	Interest, net.....			
				-----	Loss before income taxes.....	(28,857)	(47,946)	(54,406)
				-----	(114,155)	Provision for income taxes.....	500	50
				-----	\$ (29,357)	\$ (47,996)	\$ (55,906)	\$ (114,305)
				----- =====	=====	=====	=====	=====
				-----	September 30, 2000	December 31, 1999	-----	Assets: Health services division.....
	\$ 472,400	\$ 489,316	Hospital division.....	314,221	337,218			
	Corporate.....	476,524	409,440	-----	\$1,263,145	\$1,235,974	-----	=====

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 10 -- INCOME TAXES The provision for income taxes is based upon management's estimate of taxable income or loss for the year and includes the effect of certain non-deductible items such as goodwill amortization and the recording of additional deferred tax valuation allowances. The provision for income taxes for the third quarter of 2000 and 1999 included charges of \$8.3 million and \$17.2 million, respectively, related to the deferred tax valuation allowance. For the nine months ended September 30, 2000 and 1999, charges related to the deferred tax valuation allowance totaled \$16.7 million and \$33.0 million, respectively. In addition, the Company recorded a valuation allowance of \$3.4 million in the first quarter of 1999 related to the change in accounting for start-up costs. At September 30, 2000, the deferred tax valuation allowance included in the Company's unaudited condensed consolidated balance sheet aggregated \$376.7 million. NOTE 11 -- LITIGATION Summary descriptions of various significant legal and regulatory activities follow: On September 13, 1999, the Company and substantially all of its subsidiaries filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code. The Chapter 11 Cases have been styled In re: Vencor, Inc., et al., Debtors and Debtors in Possession, Case Nos. 99-3199 (MFW) through 99-3327 (MFW), Chapter 11, Jointly Administered. On September 29, 2000, the Company filed its Proposed Plan with the Bankruptcy Court. See Note 4 for further discussion of the Chapter 11 Cases. On March 18, 1999, the Company served Ventas with a demand for mediation pursuant to the Spin-off Agreement. The Company was seeking a reduction in rent and other concessions under its Master Lease Agreements with Ventas. On March 31, 1999, the Company and Ventas entered into the Standstill Agreement which provided that both companies would postpone through April 12, 1999 any claims either may have against the other. On April 12, 1999, the Company and Ventas entered into the Second Standstill which provided that neither party would pursue any claims against the other or any other third party related to the Spin-off as long as the Company complied with certain rent payment terms. The Second Standstill was scheduled to terminate on May 5, 1999. Pursuant to the Tolling Agreement, the Company and Ventas also agreed that any statutes of limitations or other time-related constraints in a bankruptcy or other proceeding that might be asserted by one party against the other would be extended and tolled from April 12, 1999 until May 5, 1999 or until the termination of the Second Standstill. As a result of the Company's failure to pay rent, Ventas served the Company with notices of nonpayment under the Master Lease Agreements. Subsequently, the Company and Ventas entered into further amendments to the Second Standstill and the Tolling Agreement to extend the time during which no remedies may be pursued by either party and to extend the date by which the Company may cure its failure to pay rent. In connection with the Chapter 11 Cases, the Company and Ventas entered into the Stipulation which provides for the payment by the Company of a reduced monthly rent of approximately \$15.1 million beginning in September 1999. The Stipulation was approved by the Bankruptcy Court. The Stipulation also continues to toll any statutes of limitations or other time constraints in a bankruptcy proceeding for claims that might be asserted by the Company against Ventas. The Stipulation automatically renews for one-month periods unless either party provides a 14-day notice of termination. The Stipulation also may be terminated prior to its expiration upon a payment default by the Company, the consummation of a plan of reorganization or the occurrence of certain defaults under the DIP Financing. The Stipulation also provides that the Company will continue to fulfill its indemnification obligations arising from the Spin-off. 20 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) If the Company and Ventas are unable to resolve their disputes or maintain an interim resolution, the Company may seek to pursue claims against Ventas arising out of the Spin-off and seek judicial relief barring Ventas from exercising any remedies based on the Company's failure to pay some or all of the rent to Ventas. The Company's failure to pay rent or comply with the Stipulation, in the absence of judicial relief, would result in an "Event of Default" under the Master Lease Agreements. Upon an Event of Default under the Master Lease Agreements, assuming Ventas were to be granted relief from the automatic stay by the Bankruptcy Court, the remedies available to Ventas include terminating the Master Lease Agreements, repossessing and reletting the leased properties and requiring the Company to (i) remain liable for all obligations under the Master Lease Agreements, including the difference between the rent under the Master Lease Agreements and the rent payable as a result of reletting the leased properties or (ii) pay the net present value of the rent due for the balance of the terms of the Master Lease Agreements. Such remedies, however, would be subject to the supervision of the Bankruptcy Court. The Company's subsidiary, formerly named TheraTx, Incorporated ("TheraTx"), is a plaintiff in a declaratory judgment action entitled TheraTx, Incorporated v. James W. Duncan, Jr., et al., No. 1:95-CV-3193, filed in the United States District Court for the Northern District of Georgia

and currently pending in the United States Court of Appeals for the Eleventh Circuit, No. 99-11451-FF. The defendants have asserted counterclaims against TheraTx under breach of contract, securities fraud, negligent misrepresentation and fraud theories for allegedly not performing as promised under a merger agreement related to TheraTx's purchase of a company called PersonaCare, Inc. and for allegedly failing to inform the defendants/counterclaimants prior to the merger that TheraTx's possible acquisition of Southern Management Services, Inc. might cause the suspension of TheraTx's shelf registration under relevant rules of the Securities and Exchange Commission. The court granted summary judgment for the defendants/counterclaimants and ruled that TheraTx breached the shelf registration provision in the merger agreement, but dismissed the defendants' remaining counterclaims. Additionally, the court ruled after trial that defendants/counterclaimants were entitled to damages and prejudgment interest in the amount of approximately \$1.3 million and attorneys' fees and other litigation expenses of approximately \$700,000. The Company and the defendants/counterclaimants both have appealed the court's rulings. The Company is defending the action vigorously. The Company is pursuing various claims against private insurance companies who issued Medicare supplement insurance policies to individuals who became patients of the Company's hospitals. After the patients' Medicare benefits are exhausted, the insurance companies become liable to pay the insureds' bills pursuant to the terms of these policies. The Company has filed numerous collection actions against various of these insurers to collect the difference between what Medicare would have paid and the hospitals' usual and customary charges. These disputes arise from differences in interpretation of the policy provisions and Federal and state laws governing such policies. Various courts have issued various rulings on the different issues, some of which have been adverse to the Company and most of which have been appealed. The Company intends to continue to pursue these claims vigorously. If the Company does not prevail on these issues, future results of operations and liquidity would be materially adversely affected. A class action lawsuit entitled A. Carl Helwig v. Vencor, Inc., et al., was filed on December 24, 1997 in the United States District Court for the Western District of Kentucky (Civil Action No. 3-97CV-8354). The class action claims were brought by an alleged stockholder of the Company's predecessor against the Company and Ventas and certain current and former executive officers and directors of the Company and Ventas. The complaint alleges that 21 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) the Company, Ventas and certain current and former executive officers of the Company and Ventas during a specified time frame violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), by, among other things, issuing to the investing public a series of false and misleading statements concerning Ventas' then current operations and the inherent value of its common stock. The complaint further alleges that as a result of these purported false and misleading statements concerning Ventas' revenues and successful acquisitions, the price of the common stock was artificially inflated. In particular, the complaint alleges that the defendants issued false and misleading financial statements during the first, second and third calendar quarters of 1997 which misrepresented and understated the impact that changes in Medicare reimbursement policies would have on Ventas' core services and profitability. The complaint further alleges that the defendants issued a series of materially false statements concerning the purportedly successful integration of Ventas' acquisitions and prospective earnings per share for 1997 and 1998 which the defendants knew lacked any reasonable basis and were not being achieved. The suit seeks damages in an amount to be proven at trial, pre-judgment and post-judgment interest, reasonable attorneys' fees, expert witness fees and other costs, and any extraordinary equitable and/or injunctive relief permitted by law or equity to assure that the plaintiff has an effective remedy. In December 1998, the defendants filed a motion to dismiss the case. The court converted the defendants' motion to dismiss into a motion for summary judgment and granted summary judgment as to all defendants. The plaintiff appealed the ruling to the United States Court of Appeals for the Sixth Circuit (the "Sixth Circuit"). On April 24, 2000, the Sixth Circuit affirmed the district court's dismissal of the action on the grounds that the plaintiff failed to state a claim upon which relief could be granted. On July 14, 2000, the Sixth Circuit granted the plaintiff's petition for a rehearing en banc. The Company is defending this action vigorously. A shareholder derivative suit entitled Thomas G. White on behalf of Vencor, Inc. and Ventas, Inc. v. W. Bruce Lunsford, et al., Case No. 98CI03669, was filed in June 1998 in the Jefferson County, Kentucky, Circuit Court. The suit was brought on behalf of the Company and Ventas against certain current and former executive officers and directors of the Company and Ventas. The complaint alleges that the defendants damaged the Company and Ventas by engaging in violations of the securities laws, engaging in insider trading, fraud and securities fraud and damaging the reputation of the Company and Ventas. The plaintiff asserts that

such actions were taken deliberately, in bad faith and constitute breaches of the defendants' duties of loyalty and due care. The complaint is based on substantially similar assertions to those made in the class action lawsuit entitled *A. Carl Helwig v. Vencor, Inc., et al.*, discussed above. The suit seeks unspecified damages, interest, punitive damages, reasonable attorneys' fees, expert witness fees and other costs, and any extraordinary equitable and/or injunctive relief permitted by law or equity to assure that the Company and Ventas have an effective remedy. The Company believes that the allegations in the complaint are without merit and intends to defend this action vigorously. A class action lawsuit entitled *Jules Brody v. Transitional Hospitals Corporation, et al.*, Case No. CV-S-97-00747-PMP, was filed on June 19, 1997 in the United States District Court for the District of Nevada on behalf of a class consisting of all persons who sold shares of Transitional Hospitals Corporation ("Transitional") common stock during the period from February 26, 1997 through May 4, 1997, inclusive. The complaint alleges that Transitional purchased shares of its common stock from members of the investing public after it had received a written offer to acquire all of Transitional's common stock and without making the required disclosure that such an offer had been made. The complaint further alleges that defendants disclosed that there were "expressions of interest" in acquiring Transitional when, in fact, at that time, the negotiations had reached an advanced stage with actual firm offers at substantial premiums to the trading price of Transitional's stock having been made which were actively being considered by Transitional's Board of Directors. The complaint asserts claims pursuant to Sections 10(b), 14(e) and 20(a) of the Exchange Act, and common law principles of negligent misrepresentation and names as defendants 22 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) Transitional as well as certain former senior executives and directors of Transitional. The plaintiff seeks class certification, unspecified damages, attorneys' fees and costs. In June 1998, the court granted the Company's motion to dismiss with leave to amend the Section 10(b) claim and the state law claims for misrepresentation. The court denied the Company's motion to dismiss the Section 14(e) and Section 20(a) claims, after which the Company filed a motion for reconsideration. On March 23, 1999, the court granted the Company's motion to dismiss all remaining claims and the case was dismissed. The plaintiff has appealed this ruling. The Company is defending this action vigorously. On April 14, 1999, a lawsuit entitled *Lenox Healthcare, Inc., et al. v. Vencor, Inc., et al.*, Case No. BC 208750, was filed in the Superior Court of Los Angeles, California by Lenox Healthcare, Inc. ("Lenox") asserting various causes of action arising out of the Company's sale and lease of several nursing centers to Lenox in 1997. Lenox subsequently removed certain of its causes of action and refiled these claims before the United States District Court for the Western District of Kentucky in a case entitled *Lenox Healthcare, Inc. v. Vencor, Inc., et al.*, Case No. 3:99 CV-348-H. The Company has asserted counterclaims, including RICO claims, against Lenox in the Kentucky action. The Company believes that the allegations made by Lenox in both complaints are without merit and intends to defend these actions vigorously. Lenox and its subsidiaries filed for protection under Chapter 11 of the Bankruptcy Code on November 3, 1999. The Company has not determined the effect, if any, such filing will have on the Company's financial condition, results of operations or liquidity. By virtue of both the Company's and Lenox's separate filings for Chapter 11 protection, the two Lenox actions and the Company's counterclaims are stayed. The Company was informed by the DOJ that the Company and Ventas are the subjects of ongoing investigations into various Medicare reimbursement issues, including hospital cost reporting issues, Vencare billing practices and various quality of care issues in the hospitals and nursing centers formerly operated by Ventas and currently operated by the Company. These investigations include some matters for which the Company indemnified Ventas in the Spin-off. In cases where neither the Company nor any of its subsidiaries are defendants but Ventas is the defendant, the Company had agreed to defend and indemnify Ventas for such claims as part of the Spin-off. The Stipulation entered into with Ventas provides that the Company will continue to fulfill its indemnification obligations arising from the Spin-off. The Company has cooperated fully in the investigations. The DOJ has informed the Company that it has intervened in several pending qui tam actions asserted against the Company and/or Ventas in connection with these investigations. In addition, the DOJ has filed proofs of claims with respect to certain alleged claims in the Chapter 11 Cases. The Company and Ventas are continuing settlement discussions with the DOJ to finalize the Government Settlement to resolve all of the DOJ investigations including the pending qui tam actions. For a summary of the terms of the proposed Government Settlement contained in the Proposed Plan, see Note 4. There can be no assurance, however, that a settlement or other resolution will be consummated with the DOJ. The following is a summary of the qui tam actions pending against the Company and/or Ventas in which the DOJ has intervened. In connection with the DOJ's

intervention, the courts ordered these previously non-public actions to be unsealed. Certain of the actions described below name other defendants in addition to the Company and Ventas. 23 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) (a) The Company, Ventas and the Company's subsidiary, American X-Rays, Inc. ("AXR"), are defendants in a civil qui tam action styled United States ex rel. Doe v. American X-Rays Inc., et al., No. LR-C-95-332, pending in the United States District Court for the Eastern District of Arkansas and served on AXR on July 7, 1997. The DOJ intervened in the suit which was brought under the Federal Civil False Claims Act and added the Company and Ventas as defendants. The Company acquired an interest in AXR when The Hillhaven Corporation ("Hillhaven") was merged into the Company in September 1995 and purchased the remaining interest in AXR in February 1996. AXR provided portable X-ray services to nursing centers (including some of those operated by Ventas or the Company) and other healthcare providers. The civil suit alleges that AXR submitted false claims to the Medicare and Medicaid programs. The suit seeks damages in an amount of not less than \$1,000,000, treble damages and civil penalties. The Company has defended this action vigorously. The court has dismissed the action based upon the possible pending settlement between the DOJ and Vencor and Ventas. In a related criminal investigation, the United States Attorney's Office for the Eastern District of Arkansas ("USAO") indicted four former employees of AXR; those individuals were convicted of various fraud related counts in January 1999. AXR had been informed previously that it was not a target of the criminal investigation, and AXR was not indicted. However, the Company received several grand jury subpoenas for documents and witnesses which it moved to quash. The USAO has withdrawn the subpoenas which rendered the motion moot. (b) The Company's subsidiary, Medisave Pharmacies, Inc. ("Medisave"), Ventas and Hillhaven (former parent company to Medisave), are the defendants in a civil qui tam action styled United States ex rel. Danley v. Medisave Pharmacies, Inc., et al., No. CV-N-96-00170-HDM, filed in the United States District Court for the District of Nevada on March 15, 1996. The plaintiff alleges that Medisave, an institutional pharmacy provider, formerly owned by Ventas and owned by the Company since the Spin-off: (1) charged the Medicare program for unit dose drugs when bulk drugs were administered and charged skilled nursing facilities more for the same drugs for Medicare patients than for non-Medicare patients; (2) improperly claimed special dispensing fees that it was not entitled to under Medicaid; and (3) recouped unused drugs from skilled nursing facilities and returned these drugs to its stock without crediting Medicare or Medicaid, all in violation of the Federal Civil False Claims Act. The complaint also alleges that Medisave had a policy of offering kickbacks, such as free equipment, to skilled nursing centers to secure and maintain their business. The complaint seeks treble damages, other unspecified damages, civil penalties, attorneys' fees and other costs. The Company disputes the allegations in the complaint. The defendants intend to defend this action vigorously. (c) Ventas and the Company's subsidiary, Vencare, Inc. ("Vencare"), among others, are defendants in the action styled United States ex rel. Roberts v. Vencor, Inc., et al., No. 3:97CV-349-J, filed in the United States District Court for the Western District of Kansas on June 25, 1996 and consolidated with the action styled United States of America ex rel. Meharg, et al. v. Vencor, Inc., et al., No. 3:98SC-737-H, filed in the United States District Court for the Middle District of Florida on June 4, 1998. The complaint alleges that the defendants knowingly submitted and conspired to submit false claims and statements to the Medicare program in connection with their purported provision of respiratory therapy services to skilled nursing center residents. The defendants allegedly billed Medicare for respiratory therapy services and supplies when those services were not medically necessary, billed for services not provided, exaggerated the time required to provide services or exaggerated the productivity of their therapists. It is further alleged that the defendants presented false claims and statements to the Medicare program in violation of the Federal Civil False Claims Act, by, among other things, allegedly causing skilled nursing centers with which they had respiratory therapy contracts, to present false claims to Medicare for respiratory therapy services and supplies. The complaint seeks treble damages, other unspecified damages, civil penalties, attorneys' fees and other costs. The Company disputes the allegations in the complaint. The defendants intend to defend this action vigorously.

24 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) (d) In United States ex rel. Kneepkens v. Gambro Healthcare, Inc., et al., No. 97-10400-GAO, filed in the United States District Court for the District of Massachusetts on October 15, 1998, the Company's subsidiary, Transitional, and two unrelated entities, Gambro Healthcare, Inc. and Dialysis Holdings, Inc., are defendants in this suit alleging that they violated the Federal Civil False Claims Act and the Medicare and Medicaid antikickback, antifraud and

abuse amendments (the "Antikickback Amendments") and committed common law fraud, unjust enrichment and payment by mistake of fact. Specifically, the complaint alleges that a predecessor to Transitional formed a joint venture with Damon Clinical Laboratories to create and operate a clinical testing laboratory in Georgia that was then used to provide lab testing for dialysis patients, and that the joint venture billed at below cost in return for referral of substantially all non-routine testing in violation of the Antikickback Amendments. It is further alleged that a predecessor to Transitional and Damon Clinical Laboratories used multiple panel testing of end stage renal disease rather than single panel testing that allegedly resulted in the generation of additional revenues from Medicare and that the entities allegedly added non-routine tests to tests otherwise ordered by physicians that were not requested or medically necessary but resulted in additional revenue from Medicare in violation of the Antikickback Amendments. Transitional has moved to dismiss the case. Transitional disputes the allegations in the complaint and is defending the action vigorously. (e) The Company and/or Ventas are defendants in the action styled United States ex rel. Huff and Dolan v. Vencor, Inc., et al., No. 97-4358 AHM (Mcx), filed in the United States District Court for the Central District of California on June 13, 1997. The plaintiff alleges that the defendant violated the Federal Civil False Claims Act by submitting false claims to the Medicare, Medicaid and CHAMPUS programs by allegedly: (1) falsifying patient bills and submitting the bills to the Medicare, Medicaid and CHAMPUS programs, (2) submitting bills for intensive and critical care not actually administered to patients, (3) falsifying patient charts in relation to the billing, (4) charging for physical therapy services allegedly not provided and pharmacy services allegedly provided by non-pharmacists, and (5) billing for sales calls made by nurses to prospective patients. The complaint seeks treble damages, other unspecified damages, civil penalties, attorneys' fees and other costs. Defendants dispute the allegations in the complaint. The Company, on behalf of itself and Ventas, intends to defend this action vigorously. (f) Ventas is the defendant in the action styled United States ex rel. Brzycki v. Vencor, Inc., Civ. No. 97-451-JD, filed in the United States District Court for the District of New Hampshire on September 8, 1997. Ventas is alleged to have knowingly violated the Federal Civil False Claims Act by submitting and conspiring to submit false claims to the Medicare program. The complaint alleges that Ventas: (1) fabricated diagnosis codes by ordering medically unnecessary services, such as respiratory therapy; (2) changed referring physicians' diagnoses in order to qualify for Medicare reimbursement; and (3) billed Medicare for oxygen use by patients regardless of whether the oxygen was actually administered to particular patients. The complaint further alleges that Ventas paid illegal kickbacks to referring healthcare professionals in the form of medical consulting service agreements as an alleged inducement to refer patients, in violation of the Federal Civil False Claims Act, the Antikickback Amendments and the Stark provisions. It is additionally alleged that Ventas consistently submitted Medicare claims for clinical services that were not performed or were performed at lower actual costs. The complaint seeks unspecified damages, civil penalties, attorneys' fees and costs. Ventas disputes the allegations in the complaint. The Company, on behalf of Ventas, intends to defend the action vigorously. 25 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) (g) United States ex rel. Lanford and Cavanaugh v. Vencor, Inc., et al., Civ. No. 97-CV-2845, was filed against Ventas in the United States District Court for the Middle District of Florida, on November 24, 1997. The United States of America intervened in this civil qui tam lawsuit on May 17, 1999. On July 23, 1999, the United States filed its amended complaint in the lawsuit and added the Company as a defendant. The lawsuit alleges that the Company and Ventas knowingly submitted false claims and false statements to the Medicare and Medicaid programs including, but not limited to, claims for reimbursement of costs for certain ancillary services performed in defendants' nursing centers and for third party nursing center operators that the United States alleges are not properly reimbursable costs through the hospitals' cost reports. The lawsuit involves the Company's hospitals which were owned by Ventas prior to the Spin-off. The complaint does not specify the amount of damages sought. The Company and Ventas dispute the allegations in the amended complaint and intend to defend this action vigorously. (h) In United States ex rel. Harris and Young v. Vencor, Inc., et al., filed in the Eastern District of Missouri on May 25, 1999, the defendants include the Company, Vencare, and Ventas. The defendants allegedly submitted and conspired to submit false claims for payment to the Medicare and CHAMPUS programs, in violation of the Federal Civil False Claims Act. According to the complaint, the Company, through its subsidiary, Vencare, allegedly (1) over billed for respiratory therapy services, (2) rendered medically unnecessary treatment, and (3) falsified supply, clinical and equipment records. The defendants also allegedly encouraged or instructed therapists to falsify clinical records and over prescribe therapy services. The complaint seeks treble damages, other unspecified



damages, civil penalties, attorneys' fees and other costs. The Company disputes the allegations in the complaint and intends to defend this action vigorously. The action has been dismissed with prejudice as to the relator and without prejudice as to the United States. (i) In United States ex rel. George Mitchell, et al. v. Vencor, Inc., et al., filed in the United States District Court for the Southern District of Ohio on August 13, 1999, the defendants, consisting of the Company and its two subsidiaries, Vencare and Vencor Hospice, Inc., are alleged to have violated the Federal Civil False Claims Act by obtaining improper reimbursement from Medicare concerning the treatment of hospice patients. Defendants are alleged to have obtained inflated Medicare reimbursement for admitting, treating and/or failing to discharge in a timely manner hospice patients who were not "hospice appropriate." The complaint further alleges that the defendants obtained inflated reimbursement for providing medications for these hospice patients. The complaint alleges damages in excess of \$1,000,000. The Company disputes the allegations in the complaint and intends to defend vigorously the action. (j) In Gary Graham, on Behalf of the United States of America v. Vencor Operating, Inc. et. al., filed in the United States District Court for the Southern District of Florida on or about June 8, 1999, the defendants, including the Company, its subsidiary, Vencor Operating, Inc., Ventas, Hillhaven and Medisave, are alleged to have presented or caused to be presented false or fraudulent claims for payment to the Medicare program in violation of, among other things, the Federal Civil False Claims Act. The complaint alleges that Medisave, a subsidiary of the Company which was transferred from Ventas to the Company in the Spin-off, systematically up-charged for drugs and supplies dispensed to Medicare patients. The complaint seeks unspecified damages, civil penalties, interest, attorneys' fees and other costs. The Company disputes the allegations in the complaint and intends to defend this action vigorously. 26 KINDRED HEALTHCARE, INC. (Formerly Vencor, Inc., a Debtor-in-Possession) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (Unaudited) NOTE 11 -- LITIGATION (Continued) (k) In United States, et al., ex rel. Phillips-Minks, et al. v. Transitional Corp., et al., filed in the United States District Court for Southern District of California on July 23, 1998, the defendants, including Transitional and Ventas, are alleged to have submitted and conspired to submit false claims and statements to Medicare, Medicaid, and other Federal and state funded programs during a period commencing in 1993. The conduct complained of allegedly violates the Federal Civil False Claims Act, the California False Claims Act, the Florida False Claims Act, the Tennessee Health Care False Claims Act, and the Illinois Whistleblower Reward and Protection Act. Defendant allegedly submitted improper and erroneous claims to Medicare, Medicaid and other programs, for improper or unnecessary services and services not performed, inadequate collections efforts associated with billing and collecting bad debts, inflated and nonexistent laboratory charges, false and inadequate documentation of claims, splitting charges, shifting revenues and expenses, transferring patients to hospitals that are reimbursed by Medicare at a higher level, failing to return duplicate reimbursement payments, and improperly allocating hospital insurance expenses. In addition, the complaint alleges that the defendants were inconsistent in their reporting of cost report data, paid kickbacks to increase patient referrals to hospitals, and incorrectly reported employee compensation resulting in inflated employee 401(k) contributions. The complaint seeks unspecified damages. The Company disputes the allegations in the complaint and intends to defend this action vigorously. In connection with the Spin-off, liabilities arising from various legal proceedings and other actions were assumed by the Company and the Company agreed to indemnify Ventas against any losses, including any costs or expenses, it may incur arising out of or in connection with such legal proceedings and other actions. The indemnification provided by the Company also covers losses, including costs and expenses, which may arise from any future claims asserted against Ventas based on the former healthcare operations of Ventas. In connection with its indemnification obligation, the Company has assumed the defense of various legal proceedings and other actions. The Stipulation entered into with Ventas provides that the Company will continue to fulfill its indemnification obligations arising from the Spin-off. The Company is a party to certain legal actions and regulatory investigations arising in the normal course of its business. The Company is unable to predict the ultimate outcome of pending litigation and regulatory investigations. In addition, there can be no assurance that the DOJ, HCFA or other regulatory agencies will not initiate additional investigations related to the Company's businesses in the future, nor can there be any assurance that the resolution of any litigation or investigations, either individually or in the aggregate, would not have a material adverse effect on the Company's results of operations, liquidity or financial position. In addition, the above litigation and investigations (as well as future litigation and investigations) are expected to consume the time and attention of the Company's management and may have a disruptive effect upon the Company's operations. NOTE 12 -- THIRD PARTY SETTLEMENTS In January 2000, the Company filed its hospital cost reports for the year ended August 31,

1999. Cost reports are filed annually in settlement of amounts due to or from the various agencies administering the reimbursement programs. These cost reports indicated amounts due from the Company aggregating \$58 million. This liability arose during 1999 as part of the Company's routine settlement of Medicare reimbursement overpayments. Such amounts are classified as liabilities subject to compromise in the unaudited condensed consolidated balance sheet and, accordingly, no funds were disbursed by the Company in settlement of such pre-petition liabilities. 27

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** Cautionary Statement Certain statements made in this Form 10-Q/A, including, but not limited to, statements containing the words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may" and other similar expressions are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are inherently uncertain, and stockholders must recognize that actual results may differ materially from the Company's expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the Company is unable to predict or control, that may cause the Company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. Factors that may affect the plans or results of the Company include, without limitation, the ability of the Company to continue as a going concern; the delays or the inability to complete and/or consummate the Company's Proposed Plan; the ability of the Company to operate pursuant to the terms of the DIP Financing; the Company's ability to satisfy the conditions to effectuate the Restated DIP; the ability of the Company to operate successfully under the Chapter 11 Cases; risks associated with operating a business in Chapter 11; adverse actions which may be taken by creditors and the outcome of various bankruptcy proceedings; adverse developments with respect to the Company's liquidity or results of operations; the Company's ability to attract patients given its current financial position; the ability of the Company to attract and retain key executives and other personnel; the effects of healthcare reform and legislation on the Company's business strategy and operations; the Company's ability to control costs including labor costs, in response to the prospective payment system, implementation of the Corporate Integrity Agreement and other regulatory actions; adverse developments with respect to the Company's settlement discussions with the DOJ concerning ongoing investigations; and the dramatic increase in the costs of defending and insuring against alleged patient care liability claims. Many of these factors are beyond the control of the Company and its management. The Company cautions investors that any forward- looking statements made by the Company are not guarantees of future performance. The Company disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments. General The business segment data in Note 9 of the Notes to Condensed Consolidated Financial Statements should be read in conjunction with the following discussion and analysis. The Company provides long-term healthcare services primarily through the operation of nursing centers and hospitals. At September 30, 2000, the Company's health services division operated 317 nursing centers (40,535 licensed beds) in 31 states and a rehabilitation therapy business. The Company's hospital division operated 56 hospitals (4,886 licensed beds) in 23 states and an institutional pharmacy business. Vencare Realignment. In the fourth quarter of 1999, the Company realigned its Vencare ancillary services business. Vencare's rehabilitation, speech and occupational therapy businesses were integrated into the Company's health services division, and its institutional pharmacy business was assigned to the hospital division. Vencare's respiratory therapy and certain other ancillary businesses were discontinued. Financial and operating data presented in the following discussion and analysis reflect the realignment of the former Vencare business for all periods presented. 28

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)** General (Continued) Reorganization. On September 13, 1999, the Company and substantially all of its subsidiaries filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code. The Company currently is operating its businesses as a debtor-in-possession subject to the jurisdiction of the Bankruptcy Court. The Company's continued operating losses, liquidity issues and the Chapter 11 Cases raise substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern and the appropriateness of using the going concern basis of accounting are dependent upon, among other things, (i) the Company's ability to comply with the terms of the DIP Financing, (ii) confirmation of the Proposed Plan or other plan of reorganization submitted by the Company under the Bankruptcy Code, (iii) the Company's ability to achieve profitable operations after such confirmation, and (iv) the Company's ability to generate

sufficient cash from operations to meet its obligations. On September 29, 2000, the Company filed its Proposed Plan with the Bankruptcy Court. The Proposed Plan and other actions during the Chapter 11 Cases could change materially the amounts currently recorded in the unaudited condensed consolidated financial statements. See Note 4 of the Notes to Condensed Consolidated Financial Statements. Spin-off. On May 1, 1998, Ventas completed the Spin-off through the distribution of Vencor common stock to its stockholders. Ventas retained ownership of substantially all of its real property and leases such real property to the Company pursuant to the Master Lease Agreements. In anticipation of the Spin-off, the Company was incorporated on March 27, 1998. For accounting purposes, the consolidated historical financial statements of Ventas became the historical financial statements of the Company upon consummation of the Spin-off. Any discussion concerning events prior to May 1, 1998 refers to the Company's business as it was conducted by Ventas prior to the Spin-off. The unaudited condensed consolidated financial statements have been prepared on the basis of accounting principles applicable to going concerns and contemplate the realization of assets and settlement of liabilities and commitments in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the resolution of the Chapter 11 Cases or other matters discussed herein. Results of Operations Regulatory Changes Legislative and regulatory activities in the long-term healthcare industry have had a significant negative impact on the Company's operating results. The Balanced Budget Act of 1997 (the "Budget Act"), contained extensive changes to the Medicare and Medicaid programs intended to reduce the projected amount of increase in payments under those programs over a five year period. Virtually all spending reductions come from reimbursements to providers and changes in program components. The Budget Act has affected adversely the revenues in each of the Company's operating divisions. The Budget Act established a Medicare prospective payment system ("PPS") for nursing centers for cost reporting periods beginning on or after July 1, 1998. While most nursing centers in the United States became subject to PPS during the first quarter of 1999, all of the Company's nursing centers adopted PPS on July 1, 1998. During the first three years, the per diem rates for nursing centers are based on a blend of facility-specific costs and Federal costs. Thereafter, the per diem rates are based solely on Federal costs. The payments received under PPS cover all services for Medicare patients including all ancillary services, such as respiratory therapy, physical therapy, occupational therapy, speech therapy and certain covered pharmaceuticals. 29 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Results of Operations (Continued) Regulatory Changes (Continued) In November 1999, the Balanced Budget Refinement Act (the "BBRA") was enacted to provide a measure of relief for some of the impact of PPS. The BBRA made a temporary 20% upward adjustment in the payment rates for the care of higher acuity patients and allowed nursing centers to transition more rapidly to the Federal payment rates. The BBRA also imposed a two-year moratorium on certain therapy limitations for skilled nursing center patients. Effective October 1, 2000, the BBRA adjusted all payment categories up by 4% for two years. In April 2000, HCFA published a proposed rule which set forth updates to the Resource Utilization Grouping ("RUG") payment rates used under PPS for nursing centers. On July 31, 2000, HCFA issued a final rule which indefinitely postponed any refinements to the RUG categories used under PPS. It also provided for the continuance of Medicare payment relief set forth in the BBRA, including the 20% upward adjustment for certain higher acuity RUG categories through September 30, 2001 and the scheduled 4% increase (effective October 2000) for all RUG categories through September 30, 2002. Despite the effects of the BBRA and the HCFA ruling discussed above, revenues recorded under PPS in the Company's health services division are substantially less than the cost-based reimbursement it received before the enactment of the Budget Act. The Budget Act also reduced payments made to the hospitals operated by the Company's hospital division by reducing incentive payments pursuant to the Tax Equity and Fiscal Responsibility Act of 1982 ("TEFRA"), allowable costs for capital expenditures and bad debts, and payments for services to patients transferred from a general acute care hospital. The reductions in allowable costs for capital expenditures became effective October 1, 1997. The reductions in the TEFRA incentive payments and allowable costs for bad debts became effective between May 1, 1998 and September 1, 1998. The reductions for payments for services to patients transferred from a general acute care hospital became effective October 1, 1998. These reductions have had a material adverse impact on hospital revenues. In addition, these reductions also may affect adversely the hospital division's ability to develop additional long-term care hospitals in the future. Under PPS, the volume of ancillary services provided per patient day to nursing center patients has declined dramatically. As previously discussed, Medicare reimbursements to nursing centers under PPS include substantially all services provided to patients, including ancillary services. Prior to the implementation of PPS, the costs of such services were

reimbursed under cost-based reimbursement rules. The decline in the demand for ancillary services is mostly attributable to efforts by nursing centers to reduce operating costs. As a result, many nursing centers are electing to provide ancillary services to their patients through internal staff or are seeking lower acuity patients who require less ancillary services. In response to PPS and a significant decline in the demand for ancillary services, the Company realigned its Vencare division in the fourth quarter of 1999 by integrating the rehabilitation, speech and occupational therapy businesses into the health services division and assigning the institutional pharmacy business to the hospital division. Vencare's respiratory therapy and other ancillary businesses were discontinued. There also continues to be state legislative proposals that would impose more limitations on government and private payments to providers of healthcare services such as the Company. Many states have enacted or are considering enacting measures that are designed to reduce their Medicaid expenditures and to make certain changes to private healthcare insurance. Some states also are considering regulatory changes that include a moratorium on the designation of additional long-term care hospitals. Regulatory changes in the Medicare and Medicaid reimbursement systems applicable to the hospital division also are being considered. There also are a number of legislative proposals including cost caps and the establishment of Medicaid prospective payment systems for nursing centers. Moreover, by repealing the Boren Amendment, the Budget Act eases existing impediments on the states' ability to reduce their Medicaid reimbursement levels.

30 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Results of Operations (Continued) Regulatory Changes (Continued) The Company could be affected adversely by the continuing efforts of governmental and private third-party payors to contain the amount of reimbursement for healthcare services. There can be no assurance that payments under governmental and private third-party payor programs will remain at levels comparable to present levels or will be sufficient to cover the costs allocable to patients eligible for reimbursement pursuant to such programs. In addition, there can be no assurance that facilities operated by the Company, or the provision of services and supplies by the Company, will meet the requirements for participation in such programs. There can be no assurance that future healthcare legislation or other changes in the administration or interpretation of governmental healthcare programs will not have a material adverse effect on the Company's results of operations, liquidity and financial position. Health Services Division - Nursing Centers Revenues increased 5% to \$421 million in the third quarter of 2000 and 4% to \$1.25 billion for the nine months ended September 30, 2000 compared to the same periods a year ago. While patient volumes did not change significantly, revenues per patient day grew 6% in the third quarter and 4% for the nine month period ended September 30, 2000 primarily as a result of increased Medicare and Medicaid funding and price increases to private payors. Medicare revenues per patient day under PPS were \$301 in the third quarter of 2000 compared to \$283 in the third quarter a year ago, and \$298 for the nine months ended September 30, 2000 compared to \$289 in the prior year. Despite a decline in patient acuity levels, the increase in Medicare reimbursement rates for both periods resulted primarily from regulatory changes associated with the BBRA and an increase in therapy services. Operating income increased 34% to \$69 million in the third quarter and 32% to \$214 million for the nine month period compared to the same periods a year ago. A substantial portion of the improvement in operating margins in both periods resulted from operating efficiencies related to the fourth quarter 1999 Vencare realignment. However, costs related to professional liability risks and doubtful accounts rose by \$5 million and \$11 million from the third quarter and first nine months of 1999, respectively. In the aggregate, operating costs (wages, benefits, supplies and other expenses) per patient day increased 2% in the third quarter and were relatively unchanged for the nine month period compared to a year ago. Health Services Division - Rehabilitation Services Revenues declined 26% to \$34 million in the third quarter of 2000 and 33% to \$102 million for the nine months ended September 30, 2000 from the respective periods last year. The decline in revenues was primarily attributable to continued reductions in the demand for ancillary services in response to fixed reimbursement rates under PPS. Approximately one-half of the revenue decline in both periods was attributable to Company-operated nursing centers. Under PPS, the reimbursement for ancillary services provided to nursing center patients is a component of the total reimbursement allowed per nursing center patient. As a result, many nursing center customers (including the Company's nursing centers) have elected to provide ancillary services to their patients through internal staff and no longer contract with outside parties for ancillary services. Rehabilitation services reported operating income of \$3 million and \$2 million for the third quarter and nine month period, respectively, compared to operating income of \$5 million and \$20 million for the same periods last year. Operating results in the third quarter of 2000 reflect \$3 million of favorable adjustments for doubtful accounts resulting from collections of past due accounts. The reduction in operating income reflects a continued

decline in 31

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)** Results of Operations (Continued) Health Services Division - Rehabilitation Services (Continued) customer demand resulting from PPS. In addition, effective January 1, 2000, revenues for rehabilitation services provided to Company-operated nursing centers approximated the costs of providing such services. Accordingly, fiscal 2000 operating results do not reflect any operating income related to intercompany transactions. While the health services division will continue to provide rehabilitation services to nursing center customers, revenues and operating income related to these services may continue to decline.

**Health Services Division - Other Ancillary Services** Other ancillary services refers to certain ancillary businesses (primarily respiratory therapy) that were discontinued as part of the Vencare realignment in the fourth quarter of 1999. Operating results for the third quarter of 2000 reflect \$2 million of favorable adjustments for doubtful accounts resulting from collections from discontinued customer accounts.

**Hospital Division - Hospitals** Revenues in both the third quarter and nine months ended September 30, 2000 increased 6% to \$244 million and \$748 million, respectively. The increase in both periods was primarily attributable to growth in patient days. Revenues per patient day remained relatively unchanged in the third quarter and nine month period compared to the respective periods a year ago. Medicare revenues recorded by the Company's hospitals in prior years included reimbursement for expenses related to certain costs associated with hospital-based ancillary services previously provided by the Vencare division to its nursing center customers. In connection with the continued settlement discussions with the DOJ, the Company has agreed to discontinue recording such revenues and has excluded such costs from its Medicare cost reports since September 1, 1999. Medicare revenues related to the reimbursement of such costs aggregated \$4 million in the third quarter of 1999 and \$18 million for the nine months ended September 30, 1999. Hospital operating income declined 11% to \$47 million in the third quarter of 2000 and declined 8% to \$154 million for the nine months ended September 30, 2000 compared to the same periods a year ago. Despite an increase in patient days, operating costs per patient day increased 5% in both periods primarily as a result of growth in labor and pharmaceutical costs. Operating income also was adversely impacted by the previously discussed reduction in Medicare reimbursement for hospital-based ancillary services.

**Hospital Division - Pharmacy** Revenues increased 27% to \$52 million in the third quarter of 2000 and increased 17% to \$149 million for the nine months ended September 30, 2000 compared to the same periods a year ago. The increases resulted primarily from growth in the number of nursing center customers. Operating income in the third quarter of both years approximated \$1 million. For the nine months ended September 30, 2000, the pharmacy business reported operating income of \$1 million compared to operating income of \$8 million for the same period of 1999. Operating income during fiscal 2000 was adversely impacted by pricing pressures associated with PPS and pharmaceutical cost increases. Supply costs as a percentage of revenues rose to 59% in the third quarter of 2000 from 52% in 1999 and rose to 62% from 54% for the comparable nine month periods.

**32 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)** Results of Operations (Continued) Corporate Overhead Operating income for the Company's operating divisions excluded allocations of corporate overhead. These costs aggregated \$30 million and \$27 million in the third quarters of 2000 and 1999, respectively, and \$87 million and \$85 million for the nine months ended September 30, 2000 and 1999, respectively. As a percentage of revenues (before eliminations), corporate overhead was 4.1% and 3.9% for the respective third quarters of 2000 and 1999, and 4.0% for both of the respective nine month periods.

**Unusual Transactions** Operating results for each period presented include certain unusual transactions. These transactions are included in other operating expenses in the unaudited condensed consolidated statement of operations for the respective periods in which they were recorded. In the third quarter of 2000, the Company recorded a \$9 million write-off of an impaired investment. Operating results for the nine months ended September 30, 2000 also included a \$5 million gain on the sale of a closed hospital. Operating results for the nine months ended September 30, 1999 included a \$15 million write-off of the Company's remaining investment in a healthcare related entity and a \$6 million charge for the cancellation of a nursing center software development project.

**Capital Costs** The Company leases substantially all of its facilities. Depreciation and amortization, rents and net interest costs aggregated \$108 million in the third quarter of 2000 compared to \$127 million for the same period last year and \$326 million and \$361 million for the nine months ended September 30, 2000 and 1999, respectively. While rents were relatively unchanged, depreciation and amortization declined primarily as a result of significant write-offs of property, equipment and goodwill in the fourth quarter of 1999 in connection with the Company's valuation of its long-lived assets required by SFAS 121. On January 1, 2000, the Company changed its goodwill amortization period from 40 years to 20 years

from the date of acquisition. The impact of this change was not material. See Note 1 of the Notes to Condensed Consolidated Financial Statements. During the pendency of the Chapter 11 Cases, the Company is continuing to record the contractual amount of interest expense related to the Credit Agreement and the rents due to Ventas under the Master Lease Agreements. No interest costs have been recorded related to the 1998 Notes since the filing of the Chapter 11 Cases. Contractual interest expense not accrued for the 1998 Notes approximated \$7 million and \$22 million for the third quarter and first nine months of 2000, respectively. Income Taxes The provision for income taxes is based upon management's estimate of taxable income or loss for the year and includes the effect of certain non-deductible items such as goodwill amortization and the recording of additional deferred tax valuation allowances. The provision for income taxes for the third quarter of 2000 and 1999 included charges of \$8 million and \$17 million, respectively, related to the deferred tax valuation allowance. For the nine months ended September 30, 2000 and 1999, charges related to the deferred tax valuation allowance totaled \$17 million and \$33 million, respectively. In addition, the Company recorded a valuation allowance of \$3 million in the first quarter of 1999 related to the change in accounting for start-up costs. At September 30, 2000, the deferred tax valuation allowance included in the Company's unaudited condensed consolidated balance sheet aggregated \$377 million.

33 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Results of Operations (Continued) Consolidated Results The Company reported a pretax loss from operations before reorganization costs of \$24 million in the third quarter of 2000 compared to \$43 million in the third quarter of 1999. For the nine months ended September 30, 2000, the Company recorded a pretax loss from operations before reorganization costs of \$44 million compared to \$102 million for the same period of 1999. Reorganization costs, consisting principally of professional fees, aggregated \$4 million and \$5 million in the third quarters of 2000 and 1999, respectively, and \$10 million and \$12 million for the respective nine month periods. The net loss from operations in the third quarter of 2000 aggregated \$29 million compared to a net loss of \$48 million in the third quarter of 1999. For the nine months ended September 30, 2000, the Company's net loss from operations totaled \$56 million compared to a net loss of \$114 million a year ago. In addition, the Company recorded a \$9 million charge in the first quarter of 1999 to reflect the change in accounting for start-up costs. See Note 3 of the Notes to Condensed Consolidated Financial Statements. Liquidity As previously discussed, the Company and substantially all of its subsidiaries filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code on September 13, 1999. The Company currently is operating its businesses as a debtor-in-possession subject to the jurisdiction of the Bankruptcy Court. On September 29, 2000, the Company filed its Proposed Plan with the Bankruptcy Court. See Note 4 of the Notes to Condensed Consolidated Financial Statements. On September 14, 1999, the Company received approval from the Bankruptcy Court to pay pre-petition and post-petition employee wages, salaries, benefits and other employee obligations. The Bankruptcy Court also approved orders granting authority, among other things, to pay pre-petition claims of certain critical vendors, utilities and patient obligations. All other pre-petition liabilities are classified in the unaudited condensed consolidated balance sheet as liabilities subject to compromise. The Company currently is paying the post-petition claims of all vendors and providers in the ordinary course of business. In connection with the Chapter 11 Cases, the Company entered into the DIP Financing aggregating \$100 million. The Bankruptcy Court granted final approval of the DIP Financing on October 1, 1999. The DIP Financing, which was initially scheduled to mature on March 13, 2000, is comprised of the Tranche A Loan and the Tranche B Loan. Interest is payable at the prime rate plus 2 1/2% on the Tranche A Loan and the prime rate plus 4 1/2% on the Tranche B Loan. Available aggregate borrowings under the Tranche A Loan were initially limited to \$45 million in September 1999 and increased to \$65 million in October, \$70 million in November and \$75 million thereafter. Pursuant to the most recent amendment to the DIP Financing, the aggregate borrowing limitations under the Tranche A Loan are limited to approximately \$48 million until maturity and are reduced for asset sales made by the Company. Borrowings under the Tranche B Loan require the approval of lenders holding at least 75% of the credit exposure under the DIP Financing. The DIP Financing is secured by substantially all of the assets of the Company and its subsidiaries, including certain owned real property. The DIP Financing contains standard representations and warranties and other affirmative and restrictive covenants. At September 30, 2000, there were no outstanding borrowings under the DIP Financing.

34 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Liquidity (Continued) Since the consummation of the DIP Financing, the Company and the DIP Lenders have agreed to several amendments to the DIP Financing. These amendments approved various changes to the DIP Financing including (i) extending the period of time for the Company to file its

plan of reorganization, (ii) approving certain transactions, (iii) revising the Company's cash plan originally submitted with the DIP Financing and (iv) revising certain financial covenants. In the most recent amendment to the DIP Financing, the parties agreed, among other things, to extend the maturity date of the DIP Financing until January 31, 2001 and to revise and update certain financial covenants. In addition, the most recent amendment extends the period of time for the Company to file a plan of reorganization and disclosure statement and an appropriate motion requesting confirmation and consummation thereof to November 22, 2000. At December 31, 1999, the Company was not in compliance with the DIP Financing covenant related to the minimum Net Amount of Eligible Accounts (accounts receivable). Since there were no outstanding borrowings under the DIP Financing at December 31, 1999, the event of default had no effect on the Company's 1999 consolidated financial statements. Effective April 12, 2000, the Company and the DIP Lenders agreed to an amendment to the DIP Financing to revise the covenant related to the minimum Net Amount of Eligible Accounts. In that amendment, the DIP Lenders also waived all events of default regarding this covenant that occurred prior to the date of the amendment. The Company was in compliance with the DIP Financing covenants at September 30, 2000. On June 12, 2000, the Company entered into the Commitment Letter with certain of the DIP Lenders to finance the Restated DIP. The Restated DIP would become effective in the event the Company became involved in a legal proceeding against Ventas. The Commitment Letter was initially scheduled to expire on August 31, 2000 unless the Company obtained Bankruptcy Court approval of the Commitment Letter and paid all fees payable upon such approval. On August 31, 2000, the Company and the certain DIP Lenders agreed to an amendment to extend the date by which Bankruptcy Court approval must be obtained through October 31, 2000. On October 23, 2000, the Company and the certain DIP Lenders agreed to a further amendment to extend the date for Bankruptcy Court approval to January 31, 2001. The Bankruptcy Court approved this latest amendment to the Commitment Letter on October 25, 2000. The consummation of the Restated DIP also would be subject to other customary conditions contained in the Commitment Letter. At this time, the Company has adjourned the hearing seeking approval of the Commitment Letter and the Restated DIP in light of the status of the current negotiations with its major constituencies to finalize the terms of the Proposed Plan. Under the Bankruptcy Code, actions to collect pre-petition indebtedness against the Company are subject to an automatic stay and other contractual obligations against the Company may not be enforced. The automatic stay does not necessarily apply to certain actions against Ventas for which the Company has agreed to indemnify Ventas in connection with the Spin-off. In addition, the Company may assume or reject executory contracts, including lease obligations, under the Bankruptcy Code. Parties affected by these rejections may file claims with the Bankruptcy Court in accordance with the reorganization process. A substantial portion of pre-petition liabilities are subject to settlement under the Proposed Plan submitted by the Company. The Proposed Plan must be voted upon by certain of the impaired creditors of the Company and approved by the Bankruptcy Court. There can be no assurance that the Proposed Plan submitted by the Company will be approved by the requisite holders of claims, confirmed by the Bankruptcy Court or that it will be consummated. If the Proposed Plan is not accepted by the required number of impaired creditors and the Company's exclusive right to file and solicit acceptance of the Proposed Plan ends, any party in interest may subsequently file its own plan of reorganization for the Company.

35 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Liquidity (Continued) A plan of reorganization must be confirmed by the Bankruptcy Court after certain findings required by the Bankruptcy Code are made by the Bankruptcy Court. The Bankruptcy Court may confirm a plan of reorganization notwithstanding the non-acceptance of the plan by an impaired class of creditors or equity holders if certain requirements of the Bankruptcy Code are satisfied. The Company was informed on April 9, 1999 by HCFA that the Medicare program had made a demand for repayment of approximately \$90 million of reimbursement overpayments by April 23, 1999. On April 21, 1999, the Company entered into the HCFA Agreement under which non-interest bearing monthly payments of approximately \$1.5 million commenced in May 1999. Beginning in December 1999, interest accrues on the balance of the overpayments at a statutory rate approximating 13.4%, resulting in a monthly payment of approximately \$2 million through March 2004. If the Company is delinquent with two consecutive payments, the HCFA Agreement will be defaulted and all subsequent Medicare reimbursement payments to the Company may be withheld. Amounts due under the HCFA Agreement aggregated \$67 million at September 30, 2000 and have been classified as liabilities subject to compromise in the Company's unaudited condensed consolidated balance sheet. The Company has received Bankruptcy Court approval to continue to make the monthly payments under the HCFA Agreement during the pendency of the Chapter 11 Cases. Liabilities Subject to Compromise "Liabilities subject to compromise" refers to

liabilities incurred prior to the commencement of the Chapter 11 Cases. These liabilities, consisting primarily of long-term debt, amounts due to third party payors and certain accounts payable and accrued liabilities, represent the Company's estimate of known or potential claims to be resolved in connection with the Chapter 11 Cases. Such claims remain subject to future adjustments based on assertions of additional claims, negotiations, actions of the Bankruptcy Court, further developments with respect to disputed claims, future rejection of executory contracts or unexpired leases, determination as to the value of any collateral securing claims, treatment under a confirmed plan of reorganization and other events. Proposed payment terms for these amounts are set forth in the Proposed Plan. All pre-petition liabilities, other than those for which the Company has received Bankruptcy Court approval to pay, are classified in the unaudited condensed consolidated balance sheet as liabilities subject to compromise. Substantially all of the liabilities subject to compromise would have been classified as current liabilities if the Chapter 11 Cases had not been filed. Cash Flows Since the filing of the Chapter 11 Cases, cash flows from operations have allowed the Company to fund post-petition obligations, sustain adequate liquidity levels and minimize borrowings under the DIP Financing. Cash flows from operations before reorganization costs totaled \$155 million for the nine months ended September 30, 2000 compared to \$167 million for the nine months ended September 30, 1999. There can be no assurance, however, that the Company can maintain its current liquidity levels during the pendency of the Chapter 11 Cases. In January 2000, the Company filed its hospital cost reports for the year August 31, 1999. Cost reports are filed annually in settlement of amounts due to or from the various agencies administering the reimbursement programs. These cost reports indicated amounts due from the Company aggregating \$58 million. This liability arose during 1999 as part of the Company's routine settlement of Medicare reimbursement overpayments. Such amounts are classified as liabilities subject to compromise in the unaudited condensed consolidated balance sheet and, accordingly, no funds were disbursed by the Company in settlement of such pre-petition liabilities.

36 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued)

Capital Resources Capital expenditures for the first nine months of 2000 aggregated \$42 million compared to \$73 million a year ago. Capital expenditures could approximate \$80 million in 2000. Management believes that its capital expenditure program is adequate to improve and equip existing facilities. Capital expenditures in both periods were financed through internally generated funds. At September 30, 2000, the estimated cost to complete and equip construction in progress approximated \$16 million. There can be no assurance that the Company will have sufficient resources to finance its capital expenditures program in 2000. Other Information The Company is a party to certain material legal actions and regulatory investigations. See Note 11 of the Notes to Condensed Consolidated Financial Statements. 37 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Condensed Consolidated Statement of Operations (Unaudited) (In thousands, except per share amounts) (Restated) ----- 2000 Quarters

	First	Second	Third	Nine	
	Month	Month	Month	Months	
Revenues.....	\$715,456	\$713,424	\$717,253	\$2,146,133	-----
Salaries, wages and benefits.....	405,313	392,383	405,510	1,203,206	
Supplies.....	93,398	94,619	92,251	280,268	Rent..... 76,220
76,788	77,870	230,878	Other operating expenses.....	122,589	122,770
and amortization.....	17,902	18,168	17,464	53,534	Interest expense..... 16,239
14,415	45,317	Investment income.....	(1,206)	(1,012)	(1,490)
-----	730,455	718,379	741,365	2,190,199	-----
income taxes.....	(14,999)	(4,955)	(24,112)	(44,066)	Loss before reorganization costs and
10,340	-----	-----	-----	-----	Reorganization costs..... 3,065
Provision for income taxes.....	500	500	500	1,500	2,530
loss.....	(18,564)	(7,985)	(29,357)	(55,906)	4,745
(261)	(262)	(261)	(784)	-----	Loss before income taxes..... (18,064)
(8,247)	\$(29,618)	\$(56,690)	=====	=====	(7,485)
Basic.....	\$ (0.27)	\$ (0.12)	\$ (0.42)	\$ (0.81)	(28,857)
(0.42)	(0.81)	Shares used in computing net loss per common share: Basic.....	(70,240)	(70,147)	(70,265)
(70,147)	(70,265)	(70,217)	Diluted.....	(0.27)	(0.12)
-----	-----	-----	-----	-----	-----

38 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Condensed Consolidated Statement of Operations (Unaudited) (In thousands, except per





	First	Second	Third	Fourth	Year
Revenues: Health services division: Nursing centers.....	\$398,374	\$397,930	\$399,907	\$398,033	\$1,594,244
Rehabilitation services.....	54,365	50,234	46,088	45,044	195,731
Other ancillary services.....	16,263	12,855	10,477	3,932	43,527
Elimination.....	(34,205)	(34,564)	(31,770)	(27,728)	(128,267)
Hospital division: Hospitals.....	434,797	426,455	424,702	419,281	1,705,235
Pharmacy.....	43,246	42,951	40,707	44,589	171,493
Elimination of pharmacy charges to Company nursing centers.....	(16,333)	(15,382)	(14,167)	(15,753)	(61,635)
Income (loss) from operations (restated):	\$700,232	\$688,892	\$681,924	\$594,593	\$2,665,641
Operating income (loss): Health services division: Nursing centers.....	\$54,963	\$55,027	\$51,722	\$7,416	\$169,128
Rehabilitation services.....	6,847	8,311	5,191	(17,458)	2,891
Other ancillary services.....	3,596	1,035	1,333	(1,798)	4,166
Hospital division: Hospitals.....	57,198	58,443	52,871	(36,462)	132,050
Pharmacy.....	3,951	3,289	585	(7,483)	342
Corporate overhead.....	(27,775)	(29,676)	(27,299)	(24,197)	(108,947)
Unusual transactions.....	(20,827)	(391,591)	(412,418)	(76,157)	(305,120)
Reorganization costs.....	(2,312)	(4,547)	(5,443)	(6,304)	(18,606)
Operating income (loss)...	96,468	71,055	78,960	(477,877)	(231,394)
Rent.....	(75,452)	(76,088)	(77,423)	(76,157)	(305,120)
Depreciation and amortization.....	(22,285)	(21,612)	(24,126)	(25,173)	(93,196)
Interest, net.....	(18,905)	(19,390)	(25,357)	(11,602)	(75,254)
Loss before income taxes.....	(20,174)	(46,035)	(47,946)	(590,809)	(704,964)
Provision for income taxes.....	50	50	50	350	500
Income tax expense.....	\$(20,224)	\$(46,085)	\$(47,996)	\$(591,159)	\$(705,464)
=====					
41 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Operating Data (Continued) (Unaudited) 2000 Quarters					
----- First Second Third Nine months ----- Nursing Center Data: End of period data: Number of nursing centers: Leased and owned.....					
Managed.....	40	41	39	320	321
of licensed beds: Leased and owned.....	36,653	36,677	36,465	4,262	4,436
Managed.....	4,262	4,436	4,070	40,915	41,113
Revenue mix %: Medicare.....	28	28	27	28	28
Medicaid.....	48	48	50	49	48
Private and other.....	24	24	23	23	24
Patient days: Medicare.....	398,329	382,933	381,890	1,163,152	1,918,732
Medicaid.....	1,918,732	1,917,429	1,960,359	5,796,520	5,796,520
Private and other.....	590,619	579,128	570,679	1,740,426	2,907,680
Hospital Data: End of period data: Number of hospitals.....	56	56	56	4,931	4,880
Number of licensed beds.....	4,931	4,880	4,886	38,336	38,573
Revenue mix %: Medicare.....	28	27	24	26	26
Medicaid.....	47	48	51	50	49
Private and other.....	25	25	25	24	25
Patient days: Medicare.....	380,748	366,272	339,303	349,965	1,436,288
Medicaid.....	1,867,554	1,911,111	1,967,721	1,972,577	7,718,963
Private and other.....	633,137	623,665	626,903	617,483	2,501,188
Income tax expense.....	2,881,439	2,901,048	2,933,927	2,940,025	11,656,439
=====					
42 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Operating Data (Continued) (Unaudited) 1999 Quarters					
----- First Second Third Fourth Year ----- Nursing Center Data: End of period data: Number of nursing centers: Leased and owned.....					
Managed.....	280	280	280	282	13
Number of licensed beds: Leased and owned.....	36,924	36,726	36,675	36,912	1,661
Managed.....	1,661	1,661	1,661	1,661	38,585
Revenue mix %: Medicare.....	28	27	24	26	26
Medicaid.....	47	48	51	50	49
Private and other.....	25	25	25	24	25
Patient days: Medicare.....	380,748	366,272	339,303	349,965	1,436,288
Medicaid.....	1,867,554	1,911,111	1,967,721	1,972,577	7,718,963
Private and other.....	633,137	623,665	626,903	617,483	2,501,188
Income tax expense.....	2,881,439	2,901,048	2,933,927	2,940,025	11,656,439
=====					
Hospital Data: End of period data: Number of hospitals.....					
Number of licensed beds.....	4,937	4,935	4,907	4,931	59
Revenue mix %: Medicare.....	59	56	55	65	58

Medicaid.....	10	10	11	11	11	Private and other.....	31	34	34	24	31	Patient days: Medicare.....	
175,953	171,011	159,739	163,273	669,976	Medicaid.....	29,939	29,675	30,674	29,561	119,849	Private and other.....	49,924	238,169
49,924	49,165	47,756	45,631	192,476	-----	-----	-----	-----	-----	255,816	249,851	238,169	

238,465 982,301 =====

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** The Company's only significant exposure to market risk is changes in the levels of various interest rates. In this regard, changes in LIBOR interest rates affect the interest paid on its borrowings. In addition, the interest rates on the DIP Financing are affected by changes in the Federal Funds rate and the prime rate of Morgan Guaranty Trust Company of New York. To mitigate the impact of fluctuations in these interest rates, the Company generally maintains a portion of its borrowings on a fixed rate, long-term basis. Prior to its financial difficulties, the Company also entered into certain interest rate swap transactions. The Company had no active interest rate swap agreements at September 30, 2000. As previously discussed, the Company filed the Chapter 11 Cases on September 13, 1999. Accordingly, all amounts disclosed in the table below are subject to compromise in connection with the Chapter 11 Cases. While the fair values of the Company's debt obligations declined significantly as a result of the Chapter 11 Cases, such amounts do not reflect any adjustments that might result from the resolution of the Chapter 11 Cases or other matters discussed herein. Under the Bankruptcy Code, actions to collect pre-petition indebtedness against the Company are subject to an automatic stay and other contractual obligations against the Company may not be enforced. In addition, the Company may assume or reject executory contracts under the Bankruptcy Code. The following table provides information about the Company's financial instruments that are sensitive to changes in interest rates. The table constitutes a forward-looking statement. For long-term debt, the table presents principal cash flows and related weighted average interest rates by expected maturity date. Interest Rate Sensitivity Principal (Notional) Amount by Expected Maturity Average Interest Rate (Dollars in thousands) Expected Maturities FAIR -----

VALUE	2000	2001	2002	2003	2004	THEREAFTER	TOTAL	9/30/00	-----
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
Liabilities: Long-term debt, including amounts due within one year: Fixed rate.....	\$ 3,174								
\$17,802 \$ 19,453 \$21,145 \$ 7,574 \$303,897 \$373,045 \$120,922	Average interest rate.....	12.00%	12.00%	12.00%					
12.00% 10.00% 10.00%	Variable rate.....	\$22,503	\$61,974	\$128,640	\$79,535	\$177,344	\$ 39,147	\$509,143	
\$417,497	(a) Average interest rate -----	(a) Interest is payable, depending on the debt instrument, certain	leverage ratios and other factors, at a rate of LIBOR plus 3/4% to 3 1/2% or the prime rate plus 2% to 3 1/2%. 44						

**SIGNATURES** Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. **KINDRED HEALTHCARE, INC.**  
 Date: August 29, 2001 /s/ EDWARD L. KUNTZ ----- Edward L. Kuntz Chairman of the Board, Chief Executive Officer and President  
 Date: August 29, 2001 /s/ RICHARD A. SCHWEINHART -----  
 ----- Richard A. Schweinhart Senior Vice President and Chief Financial Officer  
 (Principal Financial Officer) 45